Evidence map›Paper›PMID 34328253›Full record

ArticleHIV medicine2021

In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.

Owain Roberts, Hannah Kinvig, Andrew Owen, Mohammed Lamorde, Marco Siccardi, Kimberly K Scarsi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Combined Oral Contraceptives As Victims of Drug Interactions.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Owain RobertsDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Hannah KinvigDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Andrew OwenDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Mohammed LamordeInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Marco SiccardiDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID 0000-0002-3539-7867
Kimberly K ScarsiCollege of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
University of Liverpool · GBInfectious Diseases Institute · UGNebraska Medical Center · US

Funding

Pharmacological Strategies to use the Levonorgestrel Implant in HIV-infected WomenR01HD085887 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SCARSI, KIMBERLY K. · 2015 to 2020
$1.4M
NICHD NIH HHS R01 HD085887
6 · The paper itself

Abstract

objectivesThe World Health Organization recommends that all countries adopt dolutegravir-based antiretroviral therapy as the preferred regimen for all individuals living with HIV. Levonorgestrel is a commonly used hormonal contraceptive, which undergoes drug-drug interactions with some antiretrovirals, but the potential interaction between dolutegravir and levonorgestrel has not been examined. We aimed to evaluate cytochrome P450 (CYP)-mediated levonorgestrel metabolism and quantify the effects of dolutegravir on levonorgestrel apparent intrinsic clearance (CL

methodsIn vitro CYP-mediated CL

resultsLevonorgestrel clearance was mediated by multiple rhCYPs, including rhCYP3A4. Under control conditions, levonorgestrel CL

conclusionsIn summary, this in vitro study suggests that dolutegravir has the potential to increase hepatic clearance of levonorgestrel by inducing both CYP3A and non-CYP3A enzymes. The observed in vitro dolutegravir-levonorgestrel drug-drug interaction should be further examined in clinical studies.

Indexed as

HIV InfectionsLevonorgestrelCytochrome P-450 CYP3ADolutegravirHeterocyclic Compounds, 3-RingHumansOxazinesPiperazinesPyridonesCytochrome P-450 CYP3ADolutegravirHeterocyclic Compounds, 3-RingLevonorgestrelOxazinesPiperazinesPyridonescontraceptivesDMPKdrug-drug interactionspharmacokinetics

Identifiers

PMID34328253
PMCPMC9363158
OpenAlexW3186297154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.